Clinical Trial Update: Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial investigating pegylated liposomal doxorubicin plus adebrelimab with or without mirabegron for relapsed ovarian cancer; Phase 2/Phase 3 and curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Adebrelimab (adebrelimab)
• Mirabegron (mirabegron)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: Obstetrics & Gynecology Hospital of Fudan University | Conditions: Ovarian Cancer Recurrent | Phase 2, Phase 3 | Status: RECRUITING